U.S. Court of Appeals ruled in favor of Eli Lilly, confirming that the Alimta vitamin regimen patent would be infringed by competitors with an alternative salt form of pemetrexed prior to the patent expiry.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest